Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-5-FPTRP is a radiolabeled tryptophan analog developed as a positron emission tomography (PET) imaging agent for oncology. It specifically targets the Large Amino Acid Transporter 1 (LAT1), a protein that is significantly overexpressed in many types of cancer to facilitate the high demand for amino acids required for rapid cell proliferation. Unlike 18F-FDG, which measures glucose metabolism and can show high background uptake in the brain, 18F-5-FPTRP provides high-contrast imaging of tumors with low normal brain interference. It is primarily investigated for the detection and characterization of gliomas and other solid tumors, offering insights into the amino acid transport mechanisms of the tumor microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-5-FPTRP.